ARA-290: Molecular Characterization and Receptor Pharmacology — A Research Reference

Erythropoietin is a 165-residue glycoprotein whose fold is a four-helix bundle, the helices conventionally labelled A through D. ARA-290 corresponds to a surface-exposed stretch of the B helix — hence its description in the literature as a helix B surface peptide. The design logic was that the region of the parent responsible for one class of receptor engagement is spatially separable from the region responsible for another, so a peptide reproducing only the first would engage only that receptor [3].

The fragment is eleven residues with a molecular weight of approximately 1,257 daltons. It carries no carbohydrate: glycosylation is a property of the expressed parent and cannot be reproduced by chemical synthesis, so much of what defines erythropoietin as a molecule — its mass is dominated by attached sugars — is absent here by construction. The composition is acidic and polar, with a single basic residue, and there is no cysteine, so unlike its parent the fragment carries no disulfide architecture.

A Heteromeric Receptor

The pharmacological premise rests on a receptor distinction established before the peptide was designed. Erythropoietin engages the classical erythropoietin receptor as a homodimer, but it also engages a second, distinct assembly: a heteromeric receptor comprising the erythropoietin receptor subunit together with the beta common receptor subunit, also designated CD131, which is shared with several cytokine receptors [1].

That the two assemblies are pharmacologically separable is the finding the whole fragment strategy depends on. Reported in-vitro characterization describes ARA-290 as engaging the heteromeric assembly while lacking the activity at the classical homodimeric receptor that the intact parent shows [2, 3]. Subsequent work characterized the peptide specifically as an agonist at the erythropoietin/CD131 heteroreceptor, using that receptor definition as the basis for the pharmacology [4].

For experimental design this is the load-bearing point: assays that report only classical erythropoietin receptor activity are the wrong readout for this compound, and a null result there is the expected outcome rather than a negative finding.

Mass spectrometry confirms the intact molecular mass near 1,257 daltons and separates the fragment from its glycosylated parent by an enormous margin.

The compound-specific identity question concerns the amino terminus. A glutamine at the start of a peptide chain cyclizes readily to pyroglutamate, an internal ring closure that releases ammonia and leaves the molecule lighter by a defined seventeen daltons. The certificate's stated theoretical mass identifies which N-terminal form the batch carries, and a result seventeen daltons removed from expectation indicates the other form rather than a different sequence — a check that takes seconds once you know to make it and is invisible if you do not.

Reversed-phase HPLC resolves the main peak from related substances and yields the purity figure. An eleven-residue synthesis produces the familiar deletion sequences, where a residue failed to couple. The sequence-specific consideration is the asparagine, which deamidates to aspartate — a change of about one dalton that also alters charge, so it separates chromatographically as well as shifting mass.

Net peptide content accounts for counter-ions and residual water, determining how much peptide a nominal milligram figure represents.

Sealed lyophilized material is stable at ambient temperature for the duration of transit and requires no cold chain in shipping. On receipt, vials are refrigerated and kept out of direct light.

Reconstituted material is held refrigerated and used within the window the receiving facility's protocols specify, and repeated freeze-thaw cycling is avoided.

The composition is net acidic, with two acidic side chains against a single basic one. A peptide is least soluble near its isoelectric point, and for an acidic sequence that point sits low — so the mildly acidic media that suit the basic sequences elsewhere in this catalogue are the wrong default here. At eleven residues the chain dissolves readily in a suitable medium, and vigorous agitation is unnecessary.

The asparagine governs storage discipline. Deamidation proceeds slowly in solution and faster at alkaline pH, so a peptide clean at manufacture can accumulate the deamidated form while sitting in a tube — a degradation route operating after the certificate was issued rather than before it. Keeping the material dry until needed and making solutions up fresh is the mitigation. The absence of cysteine and methionine removes the common oxidation routes entirely.

ARA-290 is an investigational compound. It has not been approved by the FDA or any other regulatory authority, and no manufacturing, labeling, or quality standards for an approved product apply to it. Research material is sold strictly for laboratory research use; it must not be administered to humans or animals. Researchers are responsible for compliance with all institutional and jurisdictional requirements governing research chemicals.

Each batch of research-grade ARA-290 is accompanied by an independent certificate of analysis specific to that lot.

ARA-290 is an eleven-residue synthetic peptide of approximately 1,257 daltons corresponding to a surface-exposed stretch of the B helix of erythropoietin, carrying no carbohydrate and no disulfide architecture. Its pharmacological premise rests on the separability of two receptor assemblies engaged by the parent protein: reported characterization describes engagement of the heteromeric erythropoietin-receptor/CD131 assembly rather than the classical homodimeric receptor. Analytical verification rests on distinguishing the two possible N-terminal forms by their seventeen-dalton difference, chromatographic resolution of deletion and deamidated species, and batch-specific net peptide content.